Akorn (AKRX) Issues Weak FY12 EPS, Revs Outlook
AKRX Hot Sheet
Revenue Growth %: +103.5%Financial Fact:
BASIC (in shares): 95.01M
Today's EPS Names:
TARO, BRLI, TLB, More
Akorn, Inc. (Nasdaq: AKRX), has provided full year 2012 financial guidance. The Company’s guidance includes the expected impact of the recent product acquisition from H. Lundbeck A/S, but excludes any impact of the pending acquisition of certain assets from Kilitch Drugs (India) Limited, as well as the impact from any products for which the company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2011 conference call.
Revs: $210 - $220 million
Adjusted EPS: 42 - 45 cents.
The Street is modeling revs of $221.1 million and EPS of 45 cents.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Revs: $210 - $220 million
Adjusted EPS: 42 - 45 cents.
The Street is modeling revs of $221.1 million and EPS of 45 cents.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Auriga Starts Akorn (AKRX) at Buy; Unique Product Portfolio with Limited Competition
- Movado (MOV) Offers Strong Prelim. Q1 Results; Raises FY13 Sales Outlook
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
